Brief: U.S. FDA Approves Pfizer’S Hympavzi For The Treatment Of Two Additional Hemophilia A Or B Patient Populations With Significant Medical Need
08/06/2026 11:46
BRIEF-U.S. FDA Approves Pfizer’S Hympavzi For The Treatment Of Two Additional Hemophilia A Or B Patient Populations With Significant Medical Need June 8 (Reuters) - Pfizer Inc PFE.N:
U.S. FDA APPROVES PFIZER’S HYMPAVZI FOR THE TREATMENT OF TWO ADDITIONAL HEMOPHILIA A OR B PATIENT POPULATIONS WITH SIGNIFICANT MEDICAL NEED
PFIZER - FDA APPROVES EXPANDED INDICATION FOR PFIZER'S HYMPAVZI IN HEMOPHILIA A OR B
PFIZER - HYMPAVZI APPROVED FOR HEMOPHILIA A OR B PATIENTS 12+ WITH INHIBITORS AND CHILDREN 6-11
Source text: ID:nBw6t5La
Further company coverage: PFE.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pfizer
See all newsU.S. STOCKS ON THE MOVE-Chip stocks, Unicycive, Roblox
U.S. STOCKS ON THE MOVE-AMD, Roblox, Olin
Eli Lilly, Pfizer slip after US House panel probing China clinical trials
US House committee opens investigation into Merck, AbbVie China drug trials (updated)
Brief: U.S. House Committee Sends Letters To Pfizer, Eli Lilly & Bristol Myers Squibb Probing China Drug Trials